These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6473096)

  • 1. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Kumar A; Walenga JM; Emanuele RM; Williamson K; Hoppensteadt D
    Nouv Rev Fr Hematol (1978); 1984; 26(4):267-75. PubMed ID: 6473096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
    Jeske W; Lormeau JC; Callas D; Iqbal O; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):193-200. PubMed ID: 7660142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 12. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology of heparin].
    Hoffmann A; Markwardt F
    Z Gesamte Inn Med; 1979 Jan; 34(1):3-8. PubMed ID: 373277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the profibrinolytic actions of heparin and its fractions.
    Fareed J; Walenga JM; Hoppensteadt DA; Messmore HL
    Semin Thromb Hemost; 1985 Apr; 11(2):199-207. PubMed ID: 3875899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From heparin to synthetic antithrombotic drugs].
    Palareti G; Cosmi B
    Minerva Anestesiol; 2001 Sep; 67(9 Suppl 1):76-81. PubMed ID: 11778099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
    Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
    Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
    Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.